

UHL Research and Innovation: Quarterly Trust Board Report January 2017

Author: Director of Research & Innovation Sponsor: Medical Director

Trust Board paper M

Executive Summary

Context

UHL is a Trust active in Research and Innovation (R&I). This report describes current R&I performance against metrics, projects under development, new challenges and potential threats.

Questions

1. Is UHL performing well in the delivery of quality research at expected volume?
2. Are large projects planned with appropriate partners and managed appropriately?
3. Are upcoming challenges understood?

Conclusion

1. UHL performs well in delivering high quality research as judged by NIHR and LCRN data.
2. A larger number of large projects are in development, some being close to start date. There is a wide range of NHS and Academic partner engagement.
3. A number of challenges are recognised and planning is in place to mitigate risks.

Input Sought

Report is presented for information.

For Reference

Edit as appropriate:

1. The following objectives were considered when preparing this report:

Safe, high quality, patient centred healthcare	[Yes]
Effective, integrated emergency care	[Yes]
Consistently meeting national access standards	[Not applicable]
Integrated care in partnership with others	[Yes]
Enhanced delivery in research, innovation & ed'	[Yes]
A caring, professional, engaged workforce	[Yes]
Clinically sustainable services with excellent facilities	[Yes]
Financially sustainable NHS organisation	[Yes]
Enabled by excellent IM&T	[Yes]

2. This matter relates to the following governance initiatives:

Organisational Risk Register	[Yes]
Board Assurance Framework	[Yes]

3. Related Patient and Public Involvement actions taken, or to be taken: [Insert here]

4. Results of any Equality Impact Assessment, relating to this matter: n/a

5. Scheduled date for the next paper on this topic: [6.4.16 Trust Board]

6. Executive Summaries should not exceed 1page. [My paper does comply]

7. Papers should not exceed 7 pages. [My paper does comply]

UHL R&I Quarterly Trust Board Report January 2017

1. Introduction

This report describes current R&I performance against metrics, projects under development, new challenges and potential threats.

2. Research Performance

The activity of UHL in initiating and delivering clinical research is performance monitored by both the NIHR Central Commissioning Facility (NIHR CCF) and the East Midlands Clinical Research Network (EM CRN). In turn the UHL R&I Office reports research CMG level activity and performance to each CMG via the R&I Executive Committee.

2.1 NIHR CCF.

NIHR league tables (<http://www.nihr.ac.uk/research-and-impact/nhs-research-performance/league-tables/>) published in The Guardian show that for 15/16 UHL was the 6th highest recruiting trust in England.

In Q1 16/17 UHL initiated 104 clinical trials. These figures confirm a stable level of activity. Q2 figures – confirmation awaited from NIHR.

Table 1: UHL Performance in initiating clinical research trials

	Number of Trials Initiated		
	2014/15	2015/16	2016/17
Q1	91	107	104
Q2	79	107	Not yet available
Q3	82	116	
Q4	95	99	

UHL is also judged by its performance in recruiting patients into initiated trials within 70 days. In Q1 2016/17 this figure was >90% and represents a sustained improvement. Overall in terms of both initiating and delivering research UHL remains ranked in League 1 (of 7) by NIHR.

2.2. EM LCRN.

Recruitment into portfolio clinical trials so far for 16/17 is approximately 26% lower than the same period in 15/16. This is a whole network phenomenon – all recruiting trusts are recruiting lower numbers. Indeed the picture is mirrored nationally. UHL R&I has agreed a series of actions with LCRN ensure maximisation of recruitment.

Table 2: Cumulative Recruitment Numbers of Patients into UHL Studies 2015/16 and 16/17

	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar
Cumulative Recruitment 15/16	1078	1946	3112	4112	4972	5961	7477	9327	10112	10923	12546	13479
Cumulative Recruitment 16/17	585	1131	1671	2041	3838	4450*	5600					

*Figures in italics may be updated, *approximate figure*

3. New Awards

3.1 Designation as an NIHR Clinical Research Facility.

UHL has been successful in an application to be designated an NIHR Clinical Research Facility with an award of £1.46M for 5 years from April 2017. This is the first time UHL has received such a designation, and this will support early phase clinical trials in cancer, cardiovascular, diabetes and lifestyle, respiratory and emergency care. The NIHR assessment panel were particularly enthusiastic about plans for emergency care research in our new Emergency Department and Acute Admissions Units.

3.2 Renewal of Experimental Cancer Medicine Centre (ECMC).

UHL and University of Leicester working together have succeeded in an application to renew Leicester's ECMC. This will support early phase cancer clinical trials in the Hope Unit at LRI.

A bid to renew the Cancer Research UK Centre in Leicester was considered at the same time and was not successful.

4. Projects in Development

4.1 New Projects under Development.

4.1.1 *Research Space*

UHL's Research Space will be complete in early 2017. Composed of the existing adult CRF linked to the newly refurbished children's CRF on Level 0, Balmoral Building, LRI and re-branded as 'Research Space', this facility will provide a high quality environment for later stage clinical trials in both adults and children.

4.2. Existing Projects.

4.2.1. *The 100,000 Genome Project.*

UHL is delivering recruitment to the rare diseases component of this project above agreed trajectory. Cancer recruitment has now also begun in renal and gynae cancers with lung and breast to follow very soon.

4.2.3. The Leicester Precision Medicine Institute (LPMI).

LPMI now has a Director and a Commercial Director, and imminently a Manager. LPMI is providing invaluable support to both the BRC and CRF and other key elements of precision medicine in Leicester.

5. Innovation/Enterprise Activities

We are working with Leicester Precision Medicine Institute and the Healthcare Innovation Hub Medipex to commercialise the Stent Project and NeedleGuide – a device for safe placement of needles and cannulae.

6. New/Existing Challenges

6.1. UHL Research and Innovation Strategy Refresh.

UHL's R&I strategy is due to be updated in 2017. This will be developed in close collaboration with academic partners guided by the outcome of major funding bids.

6.2. Delivery of 100,000 Genome Project.

Recruitment remains under close scrutiny. Pathology is a pressure point. Genomics team working with relevant clinical specialities to facilitate recruitment.

6.3. Hope Unit at Glenfield

Efforts continue to identify suitable space for Hope Unit at Glenfield Hospital